Format

Send to

Choose Destination
Ann Hepatol. 2015 Jan-Feb;14(1):28-35.

Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy.

Author information

1
Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.
2
Department of Hepatology Osaka City General Hospital, Osaka Japan.
3
Internal Medicine, Izumi Municipal Hospital, Izumi, Japan.
4
Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Abstract

AIM:

Anemia is the most common adverse event in patients with chronic hepatitis C virus (HCV) treated with telaprevir (TVR) combined triple therapy. We examined the effects of drug dose adjustment on anemia and a sustained viral response (SVR) during combination therapy.

MATERIAL AND METHODS:

This study enrolled 62 patients treated with TVR (2,250 mg) for 12 weeks plus pegylated interferon-alpha-2b and ribavirin for 24 weeks. The patients were assigned randomly to the TVR-standard or -reduced groups before treatment. At the occurrence of anemia (hemoglobin < 12 g/dL), the TVR-reduced group received 1500 mg TVR plus the standard dose of ribavirin, whereas the TVR-standard group received the standard TVR dose (2,250 mg) and a reduced dose of ribavirin (200 mg lower than prescribed originally). The safety and SVR at 24 weeks were compared between the TVR-standard (n = 28) and TVR-reduced (n = 25) groups.

RESULTS:

No differences in the proportion of patients who became HCV RNA-negative were detected between the TVR-standard and -reduced groups (72 and 72% at week 4, 79 and 84% at the end of treatment, and 76 and 80% at SVR24, respectively). Two groups had comparable numbers of adverse events, which led to the discontinuation of TVR in 14 patients of TVR-standard group and in 14 of TVR-reduced group. A lower incidence of renal impairment was observed in the TVR-reduced group (6%) than the TVR-standard group (11%, not statistically significant).

CONCLUSIONS:

TVR dose adjustment could prevent anemia progression without weakening the anti-viral effect during triple therapy in HCV-patients.

PMID:
25536639
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center